Reports about an impending deal have been circulating for some time and now the companies confirm that an agreement has been reached.
Springworks, headquartered in Stamford, Connecticut, primarily focuses on precision oncology and the treatment of rare genetic diseases. The company has developed, among other things, a systemic standard-of-care therapy in adults with desmoid tumors and the first and approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.
BREAKING